VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung
KO-MEN-017
Phase 3 small_molecule active
Quick answer
VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung for NPM1-m and KMT2A-r Acute Myeloid Leukemia is a Phase 3 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kura Oncology
- Indication
- NPM1-m and KMT2A-r Acute Myeloid Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active